Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

Warwick Medical School, University of Warwick, Coventry, UK.
BMJ Open (Impact Factor: 2.06). 01/2013; BMJ Open 2013;3:e001986.. DOI: 10.1136/bmjopen-2012-001986

ABSTRACT Objectives: To synthesise current evidence for the effects of exenatide and liraglutide on heart rate, blood pressure and body weight.

Design: Meta-analysis of available data from randomised controlled trials comparing Glucagon-like peptide-1 (GLP-1) analogues with placebo, active anti-diabetic drug therapy or lifestyle intervention.

Participants: Patients with type 2 diabetes.

Outcome measures: Weighted mean differences between trial arms for changes in heart rate, blood pressure and body weight, after a minimum of 12-week follow-up.

Results: 32 trials were included. Overall, GLP-1 agonists increased the heart rate by 1.86 beats/min (bpm) (95% CI 0.85 to 2.87) versus placebo and 1.90 bpm (1.30 to 2.50) versus active control. This effect was more evident for liraglutide and exenatide long-acting release than for exenatide twice daily. GLP-1 agonists decreased systolic blood pressure by -1.79 mm Hg (-2.94 to -0.64) and -2.39 mm Hg (-3.35 to -1.42) compared to placebo and active control, respectively. Reduction in diastolic blood pressure failed to reach statistical significance (-0.54 mm Hg (-1.15 to 0.07) vs placebo and -0.50 mm Hg (-1.24 to 0.24) vs active control). Body weight decreased by -3.31 kg (-4.05 to -2.57)
compared to active control, but by only -1.22 kg (-1.51 to -0.93) compared to placebo.

Conclusions: GLP-1 analogues are associated with a small increase in heart rate and modest reductions in body weight and blood pressure. Mechanisms underlying the rise in heart rate require further investigation.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The effects of liraglutide, a glucagon-like peptide 1 receptor agonist, on heart rate over a 24-h period (24-h heart rate) and on parasympathetic modulation of heart rate among patients with type 2 diabetes were investigated by 24-h power spectral analysis (PSA) of heart rate variability. Seven consecutive male patients with type 2 diabetes received once-daily subcutaneous injection of liraglutide (0.9 mg). We performed 24-h Holter electrocardiographic recording at baseline and after treatment for 24 weeks. PSA revealed that R–R variability data were distributed in two bands: low-frequency (LF) and high-frequency (HF) power. Compared with baseline, heart rate after treatment for 24 weeks was higher at every hour, with a significant difference for 15 of the 24 h time points. LF power was significantly reduced at two measurement points, and HF power was significantly reduced at four points. In addition, heart rate was significantly increased at all points at which LF or HF power was significantly reduced after treatment with liraglutide for 24 weeks. In conclusion, liraglutide increases 24-h heart rate after treatment for 24 weeks, possibly by inhibiting cardiac parasympathetic (vagal) activity.
    03/2014; 6(1). DOI:10.1007/s13340-014-0170-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease is the leading cause of mortality in type 2 diabetes mellitus. Hyperinsulinemia is associated with increased cardiovascular risk, but the effects of exogenous insulin on cardiovascular disease progression have been less well studied. Insulin has been shown to have both cardioprotective and atherosclerosis-promoting effects in laboratory animal studies. Long-term clinical trials using insulin to attain improved diabetes control in younger type 1 and type 2 diabetes patients have shown improved cardiovascular outcomes. Shorter trials of intensive diabetes control with high insulin use in higher risk patients with type 2 diabetes have shown either no cardiovascular benefit or increased all cause and cardiovascular mortality. Glargine insulin is a basal insulin analog widely used to treat patients with type 1 and type 2 diabetes. This review focuses on the effects of glargine on cardiovascular outcomes. Glargine lowers triglycerides, leads to a modest weight gain, causes less hypoglycemia when compared with intermediate-acting insulin, and has a neutral effect on blood pressure. The Outcome Reduction With Initial Glargine Intervention (ORIGIN trial), a 6.2 year dedicated cardiovascular outcomes trial of glargine demonstrated no increased cardiovascular risk.
    Vascular Health and Risk Management 11:107-116. DOI:10.2147/VHRM.S50286
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the pharmacology, pharmacokinetics, safety, and efficacy of the glucagon-like peptide-1 receptor agonist (GLP-1 RA), dulaglutide, in the treatment of type 2 diabetes mellitus (T2D). A PubMed search was completed to identify publications from 1947 to October 2014 using the search terms dulaglutide and LY2189265. References were reviewed to identify additional resources. Articles were included if they evaluated the pharmacology, pharmacokinetics, safety, or efficacy of dulaglutide. Dulaglutide reduces both glycosylated hemoglobin (A1C) and weight by stimulating insulin secretion and suppressing glucagon in a glucose-dependent manner, delaying gastric emptying, and promoting satiety. Dulaglutide consists of 2 GLP-1 analogues that have been modified to make it a long-acting, once-weekly agent. Dulaglutide has been studied as monotherapy and in combination with metformin, glimepiride, pioglitazone, and insulin lispro. It has demonstrated superior A1C reduction compared with placebo, metformin, insulin glargine, sitagliptin, and twice-daily exenatide. It demonstrated noninferiority in A1C reduction to liraglutide. Dulaglutide changed A1C by -0.78% to -1.51%, and it changed weight by -0.35 kg to -3.03 kg. The most common adverse effects in clinical studies were nausea, vomiting, and diarrhea. Dulaglutide is the fifth GLP-1 RA approved for T2D in the United States. It is an attractive option because it is dosed once-weekly, provides A1C lowering similar to liraglutide, weight reduction similar to exenatide, and has an adverse effect profile similar to exenatide and liraglutide. © The Author(s) 2015.
    Annals of Pharmacotherapy 01/2015; 49(3). DOI:10.1177/1060028014564180 · 2.92 Impact Factor


Available from
May 29, 2014